Pharmaceuticals, Biotechnology and Life Sciences
Gilead Sciences has reported net income for the fourth quarter 2016 of $3.1 billion, which is $1.6 billion less compared to same period last year.
Amryt has secured a patent in Japan for its skin disorder drug candidate Episalvan, and it is waiting to kick off the third phase clinical trial by the end of March 2017.
U.S. Food and Drug Administration (FDA) has granted a French based biopharmaceutical company Cellectis an Investigational New Drug (IND) approval to start first phase clinical trial with UCART123 in patients with acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Allergan said on Tuesday it wants to commit to working on preventable blindness in the USA.
Advanced Oncotherapy has dropped taking legal measures against Sinophi Healthcare Limited (Sinophi), as the companies have agreed to terminate the purchase from March and October 2015.
Kiadis Pharma has started its phase III trial with its major products for blood cancer hematopoietic stem cell transplantation (HSCT) ATIR101.
Ablynx has applied its caplacizumab to European Medicines Agency for approval to use it for a form of blod clotting disorder.
Portola Pharmaceuticals has signed a $150 million royalty deal with HealthCare Royalty Partners (HCR).
Allergan’s boss Brent Saunders said that the company plans to increase dividend on an annual basis over time.
DBV Technologies has completed a Phase IIA investigator-initiated clinical trial of Viaskin Milk for the treatment of milk-induced Eosinophilic Esophagitis (EoE) in children ages 4-17 has been completed.